Entropy Technologies LP Buys Shares of 12,585 Hologic, Inc. (NASDAQ:HOLX)

Entropy Technologies LP bought a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 12,585 shares of the medical equipment provider's stock, valued at approximately $1,025,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in HOLX. Price T Rowe Associates Inc. MD increased its position in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider's stock worth $490,931,000 after purchasing an additional 2,753,016 shares during the last quarter. Swedbank AB acquired a new stake in Hologic in the first quarter valued at approximately $120,827,000. Black Creek Investment Management Inc. boosted its holdings in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock worth $173,669,000 after acquiring an additional 885,524 shares in the last quarter. Mackenzie Financial Corp raised its holdings in shares of Hologic by 1,023.3% in the second quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider's stock worth $66,506,000 after buying an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Hologic in the second quarter valued at about $39,427,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Needham & Company LLC reiterated a "buy" rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday, October 15th. Raymond James raised their price objective on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their target price on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Stephens restated an "overweight" rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Finally, Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $89.91.

Hologic Price Performance

HOLX stock traded down $1.64 during trading on Thursday, hitting $77.54. 1,657,173 shares of the stock traded hands, compared to its average volume of 1,592,855. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The stock has a market cap of $18.01 billion, a price-to-earnings ratio of 23.29, a P/E/G ratio of 2.52 and a beta of 0.98. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a 50 day simple moving average of $80.77 and a 200 day simple moving average of $78.22.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts' consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic's revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.89 EPS. Equities analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.